Two doses per year could reshape HIV prevention, but price and licensing issues may limit scalability within the Brazilian public health system (SUS). The “quasi-vaccine” developed by Gilead Sciences arrives in Brazil with rare clinical evidence and global regulatory endorsement. But the geopolitics of voluntary licenses and the pricing logic in rich markets create a dilemma: how to remunerate innovation without turning prevention into a luxury incompatible with universality

In June 2025, the US Food and Drug Administration approved a new HIV pre-exposure prophylaxis (PrEP) regimen: the long-acting injectable...

In the contemporary global landscape, the concept of an isolated national economy has become a fiction. Nations do not compete solely for...

Health innovation and the remarkable growth of the pharmaceutical sector—with a projected global revenue of USD 1.155 trillion in...